摘要
目的获取过敏性疾病患儿疾病、生活质量相关资料,并观察孟鲁司特治疗儿童过敏性疾病的疗效。方法 2008年3月至2011年5月北京第二炮兵总医院59例过敏性疾病患儿,分两组:对照组28例,按原发病常规治疗;治疗组31例,在常规治疗基础上加服孟鲁司特(5mg/d,晚睡前服),疗程3～6个月。6个月后,分别对两组及治疗组治疗前后过敏原点刺结果、临床症状、体重、心理行为、学习成绩5项指标进行评估。结果对照组与治疗组临床症状均明显改善;治疗后对照组与治疗组低体重、行为异常、学绩低分发生率分别为53.6%、38.7%,50.0%、25.8%和64.3%、41.9%,其中行为异常发生率组两组间差异有统计学意义(P<0.05)。治疗组治疗前后,低体重(≤P25)、行为异常、学绩低分发生率分别为83.9%、38.7%,74.2%、25.8%和80.6%、41.9%,差异均有统计学意义(P<0.05)。结论儿童过敏性疾病常为心身共患疾病,孟鲁司特治疗儿童过敏性疾病有效,临床综合评估更能反应临床疗效。
Obejective To observe the effect of LTRA montelukast in treating childhood hypersensitivity disease and to get data related to their life. Methods Thirty-one children with hypersensitivity disease under conventional therapy took additional montelukast （5 mg/d, h.s.）. After a course of six months, the effect was comprehensively assessed according of skin prick test result, clinical improvement, weight changes, mental activity changes and school record changes. Results After the treatment, the five assessments of 31 children had improved to different extent. And the clinical efficacy reached 100%. The improvement rates Of behavior disorder and school record had significant difference between pre-and post-treatment （P 〈 0.05）.Conclusion Montelukast is effective to treat childhood hypersensitivity disease and the clinical comprehensive assessment can better reflectthe clinical efficacy.
出处
《中国实用儿科杂志》
CSCD
北大核心
2012年第6期449-451,共3页
Chinese Journal of Practical Pediatrics
